← FDA DRUG APPROVALS

FDA ANDA · ANDA077654

CITALOPRAM HYDROBROMIDE

Sponsor: GLENMARK PHARMS LTD

APPLICATION
ANDA077654
TYPE
ANDA
ORIGINAL APPROVAL
2009-02-27
LATEST ACTION
2024-10-07
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 20MG BASE · TABLET · ORAL
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 40MG BASE · TABLET · ORAL
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 10MG BASE · TABLET · ORAL

Approval history

2024-10-07Labeling · Supplement 5 · standardAP
2023-11-20Labeling · Supplement 4 · standardAP
2022-09-16Labeling · Supplement 3 · standardAP
2022-09-16Labeling · Supplement 1 · standardAP
2022-09-16Labeling · Supplement 2 · standardAP
2009-02-27Original — Other Important Information from FDA ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →